Premium
Headache and Ophthalmoparesis: Case Report of an “Atypical” Incomplete Miller–Fisher Syndrome
Author(s) -
MorenoAjona David,
Irimia Pablo,
FernándezMatarrubia Marta
Publication year - 2018
Publication title -
headache: the journal of head and face pain
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.14
H-Index - 119
eISSN - 1526-4610
pISSN - 0017-8748
DOI - 10.1111/head.13320
Subject(s) - ophthalmoparesis , medicine , photophobia , diplopia , ataxia , anisocoria , headaches , ptosis , paresis , dermatology , differential diagnosis , pediatrics , surgery , pathology , pupil , neuroscience , psychiatry , biology
Objective To expand the differential diagnosis of headache and ophthalmoparesis by describing a case report in which anti‐GQ1b was demonstrated to be the cause. Background Anti‐GQ1b antibody syndrome refers to a clinical spectrum of conditions that share common mechanisms and overlapping manifestations, including the Miller–Fisher syndrome, pharyngeal‐cervical‐brachial weakness, and Bickerstaff brainstem encephalitis. Rare atypical cases presenting as acute ophthalmoparesis (AO) without ataxia or areflexia have been described. Headache is a rare condition in these disorders. Methods A 49‐year‐old woman with no history of headaches began experiencing an acute severe bilateral throbbing headache associated with nausea and photophobia. Five days later, she developed constant binocular horizontal diplopia. Results Bilateral paresis of both sixth nerves was noted. Her ocular fundi, tendon reflexes, and other findings of the physical exam were normal. In addition, both a brain MRI performed with gadolinium and a lumbar puncture yielded normal results. Serum anti‐GQ1b IgG was found to be positive. Her symptoms resolved completely following treatment with immunoglobulins (0.4 g/kg/day for 5 days). Conclusions This is the first reported case of AO related to anti‐GQ1b antibodies presenting with headache as its initial symptom. The presence of anti‐GQ1b antibodies should be determined in patients with headache and AO of unknown origin. Immunoglobulins could hasten the resolution of symptoms in these patients.